Product Information
TAMOXIFEN 20 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.2768 per EA under NDC 00378027493. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Feb 20, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378027493
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TAMOXIFEN CITRATEApproval Type
Generic (ANDA)
FDA Application
ANDA074732FDA Approved
2/20/2003
TE Code
AB
On Market Since
2/20/2003
Pharmacological Classes
Price Statistics
The NADAC for TAMOXIFEN 20 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 28.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2768 per EA |
|---|---|
| All-time high | $0.6125 (Aug 12, 2015) |
| All-time low | $0.2079 (Nov 20, 2024) |
| 52-week high | $0.2884 |
| 52-week low | $0.2759 |
| Median price | $0.4492 |
| Average price | $0.4349 |
| Largest weekly change | +45.1% (Jun 19, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tamoxifen Citrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Estrogen Agonist/Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TAMOXIFEN 20 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TAMOXIFEN 20 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.2768 per EA (NDC 00378027493), effective Sep 30, 2026.
How has the price of TAMOXIFEN 20 MG TABLET changed over time?
Over the history we have for it, the NADAC for TAMOXIFEN 20 MG TABLET has declined 28.5%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TAMOXIFEN 20 MG TABLET?
Since Nov 28, 2013, the NADAC for TAMOXIFEN 20 MG TABLET has ranged from a low of $0.2079 (Nov 20, 2024) to a high of $0.6125 (Aug 12, 2015), with a median of $0.4492 per EA.
Are there cheaper alternatives to TAMOXIFEN 20 MG TABLET?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TAMOXIFEN 20 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures TAMOXIFEN 20 MG TABLET?
TAMOXIFEN 20 MG TABLET (NDC 00378027493) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.